Celgene Target-Identification and Drug-Discovery Capabilities
Celgene has developed target-identification and drug-discovery technology platforms that enable the Company to proceed rapidly from target identification and validation through lead identification and optimization.
Celgene Target- and Drug-Discovery Process:
A Novel Therapy Spends the Least Amount of Time in Its Lifecycle as a Branded Treatment
Developing a new medicine takes an average of 10-15 years; the United States Congressional Budget Office reports that “relatively few drugs survive the clinical trial process.” Innovative therapies have a limited time in their lifecycle to recapture investment and fund future innovation.
Source: Drug Discovery and Development: Understanding the R&D Process. Available at www.innovation.org. Accessed 11/15/12. Congressional Budget Office. Research and Development in the Pharmaceutical Industry, 2006.
The products represented as in development and found in the product pipeline are intended for investors and members of the media to provide general information on Celgene. This information is not represented to be a complete description and is subject to change without notice. Celgene Corporation may from time to time update this information but does not warrant that will take place at any particular time nor assume any obligation to update this information.